As on 22-Sep-2023 16:10 EDT
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
---|---|---|---|---|---|---|---|
Ginkgo Bioworks Holdings Inc. Class A (DNA)
| 4.73 | 6.63 | 0.00 | -38.33 | -- | -- | -- |
S&P BSE Sensex
| 8.49 | 1.22 | 3.91 | 11.02 | 20.17 | 12.37 | 12.54 |
S&P Small-Cap 600#
| -0.96 | -4.96 | -1.70 | 6.06 | 11.70 | 1.31 | 6.60 |
2022
|
|
---|---|
Ginkgo Bioworks Holdings Inc. Class A (DNA)
| -79.66 |
S&P Small-Cap 600
| -17.42 |
S&P BSE Sensex
| 4.44 |
Stock
|
Peer Median
|
||
---|---|---|---|
Please wait... |
Stock
|
Peer Median
|
||
---|---|---|---|
Please wait... |
The total asset value of Ginkgo Bioworks Holdings Inc. Class A (DNA) stood at $ 2,609 Mln as on 31-Mar-23
The share price of Ginkgo Bioworks Holdings Inc. Class A (DNA) is $1.770000 (NYSE) as of 22-Sep-2023 16:10 EDT. Ginkgo Bioworks Holdings Inc. Class A (DNA) has given a return of -38.33% in the last 1 years.
Ginkgo Bioworks Holdings Inc. Class A (DNA) has a market capitalisation of $ 2,669 Mln as on 19-May-2023. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Ginkgo Bioworks Holdings Inc. Class A (DNA) is 2.46 times as on 19-May-2023, a -0.03% premium to its peers’ median range of 2.54 times.
Since, TTM earnings of Ginkgo Bioworks Holdings Inc. Class A (DNA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Ginkgo Bioworks Holdings Inc. Class A (DNA) and enter the required number of quantities and click on buy to purchase the shares of Ginkgo Bioworks Holdings Inc. Class A (DNA).
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
The CEO & director of Dr. Jason Kelly. is Ginkgo Bioworks Holdings Inc. Class A (DNA), and CFO & Sr. VP is Dr. Reshma P. Shetty.
The promoters of Ginkgo Bioworks Holdings Inc. Class A (DNA) have pledged 0% of the total equity as on Mar-23.
Some of the close peers are:
Company | Market Cap($ Mln) |
---|---|
134
|
|
23
|
|
21
|
|
13
|
Ginkgo Bioworks Holdings Inc. Class A (DNA) | Ratios |
---|---|
Return on equity(%)
|
-112.99
|
Return on capital employed(%)
|
--
|
Debt-to-equity ratio
|
0
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Ginkgo Bioworks Holdings Inc. Class A (DNA) was $-1,719 Mln.
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals... derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. Read more
Unlimited access to advice from India's top experts
The most comprehensive analysis of funds and stocks in India
A holistic portfolio manager to help track all your investments easily
And much more, like guides, tools, webinars, videos and eBooks.